ArticleAlzheimer's research & therapy2025

Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.

Xiaoxuan Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.